Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

NCT06180616 on ClinicalTrials.gov · last registry update 2025-07-29

A small phase 2 — 40 participants, against a typical 110. Due to report December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Royal North Shore Hospital
Sponsor type: Other
Enrollment: 40
Started: 2026-12
Primary completion: 2028-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body weight

Conditions studied

Type 1 Diabetes Mellitus · Overweight and Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.